January 22, 2021

The Globe and Mail | ‘Monumental’ moment for Canadian biotech as B.C.’s Aurinia gets FDA green light to sell new lupus drug

FDA’s approval of Lupkynis™ for the treatment of lupus nephritis is a landmark moment in the Canadian drug development space.

Read more about this monumental moment for Canadian biotech from Sean Silcoff, with comments from Brian Bloom here.